Addex Therapeutics (NASDAQ:ADXN) & Eloxx Pharmaceuticals (NASDAQ:ELOX) Head to Head Contrast

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Valuation and Earnings

This table compares Eloxx Pharmaceuticals and Addex Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36 million	9.55	-$5.99 million	($1.54)	-9.76
Addex Therapeutics	$210,000.00	21.38	-$8.12 million	($5.94)	-0.61

Eloxx Pharmaceuticals has higher revenue and earnings than Addex Therapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Addex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eloxx Pharmaceuticals and Addex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Addex Therapeutics	N/A	-134.76%	-106.00%

Risk & Volatility

Eloxx Pharmaceuticals has a beta of -1862.26, indicating that its share price is 186,326% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Insider and Institutional Ownership

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Eloxx Pharmaceuticals and Addex Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1	0	2	2	3.00
Addex Therapeutics	1	0	0	0	1.00

Eloxx Pharmaceuticals presently has a consensus price target of $38.33, suggesting a potential upside of 155.05%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Eloxx Pharmaceuticals is more favorable than Addex Therapeutics.

Summary

Eloxx Pharmaceuticals beats Addex Therapeutics on 10 of the 14 factors compared between the two stocks.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.